Latest news for Mobotix (OTC:MBTXF) Stock

Mobotix AG manufactures video management systems and IP cameras. The products of the company are Mobotix 7, Mobotix Sync, outdoor cameras, indoor cameras, thermographic cameras, optics and software, home automation and accessories. The company also develops technologies such as light sensitivity, thermal, motion analysis, object statistics, behavioral analytics, and heatmap.

MOBOTIX AG ORD by Mobotix AG, Kaiserslautern

Mobotix AG

Benchmark analyst Bruce Jackson initiates coverage on Movano (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOVE#NASDAQ">MOVE</a>) with a Speculative Buy rating and announces Price Target of $2.

News

Price Target

Initiation

Analyst Ratings

MOVE

Benchmark Initiates Coverage On Movano with Speculative Buy Rating, Announces Price Target of $2

Truist Securities analyst Bill Chappell maintains Newell Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) with a Hold and raises the price target from $8 to $10.

Truist Securities Maintains Hold on Newell Brands, Raises Price Target to $10

The following table reconciles our FFO, Core FFO and AFFO guidance to our net loss (the most directly comparable GAAP financial measure) guidance for the year ended December 31, 2024 (in thousands, except per share data):
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="2" rowspan="1">
For the Year Ended
December 31, 2024
</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="2" rowspan="1">Mid-Point</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net loss</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">(30,170)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Depreciation and amortization</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">97,741</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Gain on sales of real estate</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">(50,395)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjustment for noncontrolling interests</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">(99)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">FFO attributable to common stockholders</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">17,077</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">FFO per share - diluted (1)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">0.65</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Loss on extinguishment of debt and modification costs</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">52,973</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Casualty-related expenses</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">802</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Amortization of deferred financing costs - acquisition term notes</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">872</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Gain on forfeited deposits</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">—</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjustment for noncontrolling interests</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">(207)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Core FFO attributable to common stockholders</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">71,517</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Core FFO per share - diluted (1)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">2.72</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Amortization of deferred financing costs - long term debt</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">1,359</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Equity-based compensation expense</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">10,601</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjustment for noncontrolling interests</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">(46)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">AFFO attributable to common stockholders</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">83,431</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">AFFO per share - diluted (1)</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">3.18</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Weighted average common shares outstanding - diluted</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">26,246</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
</tbody>
</table>
</figure><figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">(1)</td>
<td colspan="1" rowspan="1">For purposes of calculating per share data, we assume a weighted average diluted share count of approximately 26.2 million for the full year 2024.</td>
</tr>
</tbody>
</table>
</figure>
NOI
The following table, which has not been adjusted for the effects of noncontrolling interests, reconciles NOI for the three months ended March 31, 2024 and the year ended December 31, 2023 to net income, the most directly comparable GAAP financial measure (in thousands):

Guidance

NXRT

NexPoint Residential Sees FY24 FFO $0.65 Per Diluted Share; Core FFO $2.72 Per Diluted Share; AFFO $3.18 Per Diluted Share

Truist Securities analyst Jake Bartlett maintains McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) with a Buy and lowers the price target from $300 to $295.

Truist Securities Maintains Buy on McDonald's, Lowers Price Target to $295

Dividends

BGC Declares Quarterly Qualified Cash Dividend Of $0.02

Truist Securities analyst Richard Newitter maintains Integra Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) with a Hold and lowers the price target from $32 to $26.

IART

Truist Securities Maintains Hold on Integra Lifesciences, Lowers Price Target to $26

Backed By Alberta Indigenous Opportunities Corporation, Implied Enterprise Value Of $1.65B

TC Energy Announces $1B Equity Interest Purchase Agreement With Indigenous Investment Partnership For 5.34% Stake In NGTL And Foothills Pipeline Assets

<ul>
<li>Ongoing open-label extension trials of simufilam in Alzheimer's disease to be extended by up to an additional 36 months.</li>
<li>The extension provides participants the opportunity to continue on treatment, if they desire, pending results of the ongoing pivotal Phase 3 trials.</li>
<li>Company plans to add cognition and plasma biomarker monitoring to the open-label extension trials to gather additional long-term data on simufilam treatment.</li>
</ul>
AUSTIN, Texas, July 30, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) today announced that the Company will extend by up to an additional 36 months each of the open-label extension trials in its ongoing Phase 2 and Phase 3 clinical programs. These amendments to the protocols will allow patients who have previously participated in a randomized trial of simufilam in Alzheimer's disease, if they desire, to continue open-label treatment with simufilam. This expansion of the open-label extension trials offers a bridge for any gap between patients ending treatment in a clinical trial and the Company reporting to regulatory authorities the results of the ongoing, randomized, placebo-controlled Phase 3 trials. The open-label extension can continue for up to 36 months or until a new drug application for simufilam has been reviewed by FDA.

Biotech

General

SAVA

Cassava Sciences Announces Expansion Of Open-Label Extension Trials By Up To An Additional 36 Months To Provide Participants The Opportunity To Continue On Treatment, If They Desire, Pending Results Of The Ongoing Phase 3 Trials

BGC Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGC#NASDAQ">BGC</a>) reported quarterly earnings of $0.23 per share which met the analyst consensus estimate. This is a 15 percent increase over earnings of $0.20 per share from the same period last year. The company reported quarterly sales of $550.76 million which beat the analyst consensus estimate of $545.00 million by 1.06 percent. This is a 11.70 percent increase over sales of $493.08 million the same period last year.

Earnings

Earnings Beats

BGC Partners Q2 Adj $0.23, Inline, Sales $550.76M Beat $545.00M Estimate

WIIM

FBMS

First Bancshares are trading higher after the company announced it will be acquired by Renasant Corporation in an all-stock transaction valued at $1.2 billion.

Benchmark analyst Mark Zgutowicz reiterates DoorDash (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) with a Buy and maintains $150 price target.

Reiteration

DASH

Benchmark Reiterates Buy on DoorDash, Maintains $150 Price Target

SNK01, a cryopreserved autologous non-genetically modified NK cell product, is able to effectively reduce α-synuclein (α-syn) protein levels in the cerebral spinal fluid (CSF) of Alzheimer's patients; an important finding since increased α-syn has been correlated with worse cognitive performance and is not a target for any currently approved Alzheimer's treatments &nbsp;
SNK01 treatment appears to stabilize or improve cognitive function and reduce α-synuclein levels in CSF in addition to improving previously reported amyloid, tau, and neuroinflammatory markers (GFAP, NfL, YKL-40) in the majority of patients
SANTA ANA, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, today announced the presentation of a poster entitled, "Subjects treated with expanded non-genetically modified autologous Natural Killer cells (SNK01) show improved changes in CSF α-synuclein and in cognitive function." SNK01 is a first-in-kind, autologous non-genetically modified NK cell product with significantly increased cytotoxicity and over 90% activating receptor expression that can be consistently produced from any donor. Clinical trial data on the effect of SNK01 α-synuclein and cognitive assessments in patients with Alzheimer's Disease ("AD") was presented at the 2024 Alzheimer's Association International Conference ("AAIC") held in Philadelphia, PA on July 30, 2024.

NKGN

NKGen Biotech Presents New SNK01 Biomarker Data At The 2024 AAIC Held On July 30, 2024

Easy Installation And Significant Performance Enhancements

COMM

CommScope Launches STARLINE 1.8 GHz ESD Amplifiers For DOCSIS 3.1 Networks; Provides Upgrade Path To DOCSIS 4.0

NexPoint Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXRT#NYSE">NXRT</a>) reported quarterly earnings of $0.68 per share which beat the analyst consensus estimate of $0.64 by 6.25 percent. The company reported quarterly sales of $64.200 million which missed the analyst consensus estimate of $64.750 million by 0.85 percent. This is a 7.76 percent decrease over sales of $69.600 million the same period last year.

Earnings Misses

NexPoint Residential Q2 2024 FFO $0.68 Beats $0.64 Estimate, Sales $64.200M Miss $64.750M Estimate

Truist Securities analyst Michael Lewis maintains Highwoods Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIW#NYSE">HIW</a>) with a Buy and raises the price target from $29 to $33.

Truist Securities Maintains Buy on Highwoods Props, Raises Price Target to $33

In the picturesque town of Seeley Lake, Montana, surrounded by beautiful forests, Pyramid Mountain Lumber has been the heartbeat of the community for 75 years. But now, despite abundant wood, the mill is closing its doors for the most surprising reason: the town lacks a centralized sewer system.
Don't Miss:
<ul>
<li>A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends<a href="https://www.benzinga.com/money/arrived-private-credit-fund"> would you invest in it</a>?</li>
</ul>
Pyramid Mountain Lumber, the town's biggest employer, has been a family-owned business since 1948. Todd Johnson, whose grandfather started the mill, has worked there his entire life. &#8220;I&#8217;ve never drawn a paycheck from any other business in my whole life. I started here in sixth grade,&#8221; Johnson shared. &#8220;This is all I&#8217;ve ever known.&#8221;
The closure is not due to political battles or environmental issues. Instead, it's because the town doesn&#8217;t have a centralized sewer system, which prevents new affordable housing from being built. This makes it difficult to attract and retain workers.&nbsp;
Johnson explains, &#8220;There hasn&#8217;t been an apartment, duplex, or fourplex built in this town in over 30 years, so … when you&#8217;re talking about entry-level housing for more blue-collar workers, there&#8217;s just none available.&#8221;
Trending: Finally allowing commercial real estate investing to be more accessible —<a href="https://www.benzinga.com/money/equitymultiple-ascent-fund"> This fund aims to triple your money in 10 years is with a surprisingly low minimum.</a>
Missoula County officials explain that developers can&#8217;t build cost-effective housing for the mill's blue-collar workers without a sewer system. High-end septic systems are too expensive for the kind of housing needed in Seeley Lake. The town has debated installing a sewer system for years, but residents have consistently voted against it due to concerns about costs and changing the town&#8217;s character.
The impact of this decision is now hitting home. Pyramid Mountain Lumber, which cuts various sizes of lumber and has grown significantly over the decades, cannot find enough workers to keep running. &#8220;To make the announcement to the crew was probably the toughest thing,&#8221; Johnson told ABC News. &#8220;I&#8217;ve got friends, family, generations of good friends that work here. I had to tell them we&#8217;re going to shut the doors.&#8221;
The shortage of workers isn't just affecting the mill. Kyle Marx, the general manager of Rovero's Hardware, mentioned they&#8217;re &#8220;running on a skeleton crew&#8221; during their busiest season. &#8220;No affordable housing here,&#8221; Marx said. &#8220;Rentals have diminished since COVID hit, and everybody came up here, bought every rental that was available, and turned them into vacation rentals or moved up here themselves.&#8221;
See Also: This billion-dollar fund has invested in the next big real estate boom,<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> here's how you can join for $10.</a>
Dee Baker, who owns the Grizzly Claw Trading Company, said this has been a problem for years. "There could be low-income housing built, but the people in the town cannot come to an agreement with Missoula County," she said.
Dave Strohmaier, chair of the Missoula Board of County Commissioners, explained the irony of the situation. &#8220;The lack of infrastructure is a big reason why Pyramid Mountain Lumber cannot find housing for their employees, and hence, change is upon us,&#8221; he said.
With the mill's payroll contributing over $6 million a year to the local economy, its closure will change the fabric of Seeley Lake. &#8220;You take that out of this economy, it&#8217;ll change the fabric of the town. There&#8217;s no doubt,&#8221; Johnson noted.
Although surrounded by abundant natural resources, Seeley Lake faces a future where its long-standing timber industry might disappear, all because there isn't a place for workers to live.
Read Next:
<ul>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that lets you seize the private credit boom.</a></li>
<li>A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a></li>
</ul>

Real Estate

Although There's An Abundance Of Wood, This 75-Year-Old Mill In Montana Is Closing For The Most Surprising Reason

aTyr Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATYR#NASDAQ">ATYR</a>) ("aTyr" or "the Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that it has entered into a research agreement with Stanford Medicine. Michael Lim, M.D., Chair of the Department of Neurosurgery at Stanford Medicine, will serve as the principal investigator for the study. Dr. Lim's research focuses on understanding the basic mechanisms of immunosuppression in glioblastoma multiforme (GBM).

ATYR

aTyr Pharma Announces Research Study with Stanford Medicine Focusing On Understanding The Basic Mechanisms Of Immunosuppression In Glioblastoma Multiforme

Truist Securities analyst Anthony Hau maintains Equity Lifestyle Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELS#NYSE">ELS</a>) with a Hold and raises the price target from $65 to $70.

Truist Securities Maintains Hold on Equity Lifestyle Props, Raises Price Target to $70

HEES

H&E Equipment Services shares are trading lower after the company reported worse-than-expected Q2 financial results.

<ul>
<li>Launching into this growth market1 as part of the company's geographic expansion strategy</li>
<li>Evolus Australia established to drive medical education, training, marketing and sales to medical aesthetics healthcare professionals</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.evolus.com%2F&amp;esheet=54099911&amp;newsitemid=20240730657453&amp;lan=en-US&amp;anchor=Evolus%2C+Inc.&amp;index=1&amp;md5=1f4593444d661564b0233037f1f5dd5a">Evolus, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOLS#NASDAQ">EOLS</a>), a performance beauty company focused on building an aesthetic portfolio, has commenced operations in Australia with the launch of Nuceiva&#xAE; (prabotulinumtoxinA).
Nuceiva&#xAE; is approved by the Therapeutic Goods Administration (TGA) for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients2.

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

Mobotix

News

Latest news for Mobotix (OTC:MBTXF) Stock